FBXO5 and cancer: So, while EMI1 has traditionally been described as an oncogene—it is frequently overexpressed in many cancer types where it is associated with disease development, progression, therapeutic resistance and poor patient outcomes [31, 63, 64]—our data are consistent with EMI1 also possessing tumour suppressor-like properties, as its reduced expression induces CIN and cellular transformation.